Please ensure Javascript is enabled for purposes of website accessibility

Why Akebia Therapeutics Shares Soared 33.4% Today

By Todd Campbell - Apr 26, 2017 at 5:45PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An expanded licensing pact with Otsuka boosted investors' optimism.

What happened

After inking an expanded deal with Otsuka Pharmaceutical on its midstage anemia drug, shares of Akebia Therapeutics (AKBA -15.40%) skyrocketed 33.4% today. 

So what

Otsuka already had licensing rights to Akebia Therapeutics' vadadustat in the U.S. thanks to a deal cut between the two companies in December, and now, Otsuka has nailed down rights to vadadustat in Europe, China, Russia, Canada, Australia, and the Middle East. 

Two business people shake hands.

Image source: Getty Images.

Vadadustat is an oral drug that can boost red blood cell counts in patients with chronic kidney disease, and if its trials are successful, it could compete against Amgen Inc.'s Epogen in a multibillion-dollar market. 

In December, Otsuka paid $125 million upfront, plus additional future payments, for co-commercialization rights to vadadustat in the United States. Including milestones, Akebia could receive more than $1 billion from Otsuka, plus half of any profit on U.S. sales.

Today, Otsuka agreed to pay Akebia $73 million upfront, plus additional future payments, to secure rights to vadudustat in even more markets. In this new deal, Akebia could collect $657 million in milestone payments (plus another $135 million in development funding), as well as a royalty on sales of up to 30% in these territories.

Now what

In addition to its deal with Otsuka, Akebia has also licensed rights to vadadustat in Japan, Taiwan, South Korea, Indonesia, India, and elsewhere to Mitsubishi Tanabe Pharma. In that deal, Akebia received $40 million up front ($20 million is refundable depending on conversations with Japan's regulators), plus up to $250 million in milestones, and royalties.

Clearly, these big Japanese drugmakers think vadadustat's got a very good chance at getting across the regulatory finish line, and because both of these companies have a big sales presence in their respective markets, there's reason to think that vadudustat could hit the ground running.

First, however, phase 3 studies have to confirm vadadustat's efficacy and safety, and there's no guarantee of that happening. Therefore, while there's unquestionably a big market opportunity for Akebia, this remains a risky stock.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Akebia Therapeutics, Inc. Stock Quote
Akebia Therapeutics, Inc.
$0.38 (-15.40%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.